Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Meets Nasdaq Listing Requirement for $2.5M Stockholder Equity

Premium

Rosetta Genomics said this week that its shares will remain listed on the Nasdaq after the company regained compliance with the exchange's $2.5 million minimum stockholders' equity requirement.

The company still needs to comply with the Nasdaq's minimum $1 bid price requirement, and has until Aug. 8 to do so, it said.

"As a result of our recently announced private placement and concurrent registered offerings and the successful initial public offering in Israel of our majority-owned subsidiary Rosetta Green, we were successful in increasing stockholder equity beyond Nasdaq's listing requirement,” Rosetta President and CEO Kenneth Berlin said in a statement.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.